HRTX
Heron Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.34
+4.21%Margins
Gross margin
70.1%
EBITDA margin
-18.4%
EBIT margin
-7.2%
Net margin
-22.5%
FCF margin
-8.0%
-492.9%
Return on equity
-13.5%
Return on assets
-7.0%
Return on invested capital
0.61x
Asset turnover
-$11.6M
Cash from operations
$0.22
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026